Infliximab is equivalently suppressing oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.

Infliximab is equivalently suppressing oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.